Elacestrant Earns EU Approval for ESR1+, ER+, HER2– Advanced Breast Cancer
The regulatory decision to approve elacestrant in European patients with estrogen receptor–positive, HER2-negative locally advanced or metastatic breast cancer and an activating ESR1 mutation was based on data from the phase 3 EMERALD study.
"Today’s approval gives us the first-ever treatment option that directly acts against the very mutations that make this form of breast cancer more difficult to treat, and provides hope to our patients and their families," according to Giuseppe Curigliano, MD, PhD.
The European Commission has granted approval to elacestrant (Orserdu) for those with ESR1-mutant, estrogen receptor (ER)–positive, HER2-negative locally advanced or metastatic breast cancer who progressed after a minimum of 1 line of endocrine therapy including a CDK4/6 inhibitor, according to a press release from the Menarini Group.1
The approval was based on findings from the phase 3 EMERALD study (NCT03778931) in which patients treated with elacestrant experienced a statistically significant progression-free survival benefit over standard of care at a median of 3.8 months and 1.9 months, respectively. This translated to a 45% reduction in risk of progression or death (HR, 0.55; 95% CI, 0.39-0.77).
Frequent adverse effects associated with elacestrant include nausea, triglyceride increase, cholesterol increase, vomiting, fatigue, dyspepsia, diarrhea, calcium decrease, back pain, creatinine increase, arthralgia, sodium decrease, constipation, headache, hot flush, abdominal pain, anemia, potassium decrease, and alanine aminotransferase increase.
“With a significant number of patients [with ER–positive, HER2-negative disease] ultimately developing ESR1 mutations at some point in their metastatic journey, it is important to test for ESR1 each time a patient [with metastatic breast cancer] experiences disease progression, to understand what is fueling their [disease],” Giuseppe Curigliano, MD, PhD, professor of Medical Oncology at the University of Milano and the head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy, said in the press release. “Today’s approval gives us the first-ever treatment option that directly acts against the very mutations that make this form of breast cancer more difficult to treat, and provides hope to our patients and their families.”
Elacestrant was approved by the FDA in January 2023 for those with ER–positive, HER2-negative, ESR1-mutant advanced or metastatic breast cancer following a minimum of one line of therapy along with the Guardant 360 CDx assay.2 This decision was also based on data from the phase 3 EMERALD study.
References
- European Commission approves Menarini Group’s ORSERDU® (Elacestrant) for the treatment of patients with ER+, HER2- locally advanced or metastatic breast cancer with an activating ESR1 mutation. News release. The Menarini Group. September 20, 2023. Accessed September 20, 2023. https://bit.ly/3riFDVz
- FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. News release. FDA. January 27, 2023. Accessed September 20, 2023. bit.ly/3kQrxHq
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
FDA Approves FoundationOne CDx for Capivasertib Combo in Breast Cancer
November 21st 2023Companion diagnostic designation for FoundationOne CDx may improve access to treatment with capivasertib plus fulvestrant among patients with hormone receptor–positive, HER2-negative breast cancer harboring select alterations.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.
